Key Highlights

  • Ryoncil delivered preliminary net revenue of USD 36 million in the June quarter and USD 115 million for FY2026, its first full year on market and inside company guidance of USD 110-120 million.
  • No price-sensitive announcement preceded the fall; the last such disclosure was the 14 July confirmation that 300 patients had been treated in the pivotal chronic low back pain trial, with topline data due mid-2027.
  • Cash of USD 121.8 million at 31 March was supplemented by a USD 50 million June drawdown from a related-party facility, while shares on issue have expanded about 13 per cent since mid-2024.
  • The investment case is moving from regulatory approval towards commercial uptake, manufacturing delivery and pipeline execution.

The first company to win FDA approval for a mesenchymal stromal cell therapy has finally banked a full year of product revenue. Its shares eased anyway, leaving investors to weigh a genuine commercial start against a long history of regulatory delay.

Why the stock is in focus

For more than a decade Mesoblast Limited was defined by what the US Food and Drug Administration would not approve. It is now judged on what it can sell.

Ryoncil (remestemcel-L-rknd) became the first mesenchymal stromal cell therapy the FDA has licensed for any indication when it was cleared in December 2024 for steroid-refractory acute graft-versus-host disease in children two months and older. The question has since shifted from regulatory binary to commercial execution.

The share-price movement

A TradingView screener of Australian decliners recorded ASX:MSB at around AUD 2.06, down roughly 3.7 per cent in a single session. That figure is a point-in-time screener reading rather than a verified closing price, and Kalkine has not been able to independently confirm it against official ASX market data. A second screener snapshot put the fall nearer 3.3 per cent.

Mesoblast lodged no price-sensitive announcement in the days before the move. Two notices of investors ceasing to be substantial holders were filed on 22 and 24 July, but such filings are routine. No single confirmed company-specific catalyst was identified for the share-price movement.

Latest announcement or development

The most recent price-sensitive disclosure came on 14 July, when Mesoblast confirmed 300 patients had been treated in MSB-DR004, its pivotal Phase 3 study of rexlemestrocel-L in chronic low back pain. The sham-controlled trial is powered to detect a difference in pain reduction at 12 months, an endpoint the FDA agreed in January could support approval, with data due mid-2027.

On 1 July it received a Biologics License Application filing number for rexlemestrocel-L in preventing gastrointestinal bleeding from right ventricular dysfunction in end-stage heart failure patients on a left ventricular assist device, and requested a modular review, an administrative step rather than a completed submission.

Recent financial and operational performance

On 10 July Mesoblast reported preliminary, unaudited Ryoncil net revenue of USD 36 million for the June quarter and USD 115 million for FY2026, inside the USD 110-120 million range flagged at the half year. The lift from USD 30.3 million in March was the first meaningful sequential step in two quarters.

For the December half, revenue was USD 51.3 million, being USD 48.7 million of net product sales plus USD 2.7 million of royalties, against USD 3.2 million a year earlier. Gross profit excluding amortisation reached USD 44.2 million against USD 7.7 million of direct selling costs, while the net loss narrowed to USD 40.2 million, or 3.11 US cents per share, on research and commercialisation spending of USD 46.2 million.

Operationally, 49 transplant centres were onboarded against a target of 64 covering about 94 per cent of US paediatric transplants, with claimed payer access across some 280 million American lives.

Business model and principal assets

Mesoblast develops allogeneic, off-the-shelf cell therapies, expanding mesenchymal lineage cells from a single donor harvest into thousands of doses, giving it economics quite unlike patient-specific therapies. Management says a second-generation process yields six times more output per unit of time.

The principal assets are Ryoncil; rexlemestrocel-L for heart failure and back pain; and a Japanese royalty from TEMCELL, licensed to JCR Pharmaceuticals, which now secures the debt. Mesoblast is dual-listed, with Nasdaq depositary shares under MESO each representing ten ordinary shares.

Growth opportunities

The nearest avenue is a Ryoncil label extension into adult steroid-refractory acute graft-versus-host disease, where a Phase 3 protocol was finalised after an FDA meeting and the eligible population is roughly three times the paediatric group. The LVAD filing is narrower but faster, carrying Regenerative Medicine Advanced Therapy and orphan drug designations.

Chronic low back pain is the larger ambition: Mesoblast cites more than seven million affected Americans and peak revenue above USD 10 billion at single-digit penetration, a company estimate resting on a trial that has not read out.

Balance sheet, funding and cash flow

Cash fell from USD 161.6 million at 30 June 2025 to USD 121.8 million at 31 March 2026, though operating outflow narrowed from USD 30.3 million across the December half to USD 4.1 million in the March quarter.

The debt stack was overhauled in December 2025. A USD 125 million five-year facility at 8 per cent fixed funded extinguishment of the Oaktree loan for USD 41.7 million and a USD 25 million repayment of NovaQuest, a revenue-based facility carrying 15 per cent that matured on 8 July 2026. Total borrowings were USD 126.9 million at 31 December. The final USD 50 million tranche was drawn on 25 June, secured solely against the TEMCELL royalty, from Dr Gregory George, a shareholder and director, making it a related-party deal.

The March quarterly headline of 41.8 quarters of funding is an artefact of one light quarter, not a decade of runway. And dilution persists: shares on issue rose from 1,141.8 million at 30 June 2024 to 1,290.3 million eighteen months later.

Principal risks

The regulatory record is the clearest risk marker. Remestemcel-L drew complete response letters in late 2020, when the FDA sought a further randomised controlled study, and again in August 2023 seeking more data including potency assay evidence. Manufacturing consistency and potency assay validation sat at the centre of both refusals and remain the sensitive part of any new submission.

Commercially, revenue rests on a narrow paediatric population and centre-by-centre activation, with 15 target sites still to come. Coverage looks broad, but the gap between gross and net sales ran to roughly USD 8 million in the December half. And FDA agreement that an endpoint is approvable is no guarantee a trial will meet it.

Valuation and investor expectations

The screener implies a market capitalisation near AUD 2.88 billion and earnings per share of about negative AUD 0.11. A price-to-earnings multiple is therefore meaningless: Mesoblast is loss-making at group level even though product sales are gross-profitable.

Price to sales is more workable, though revenue is earned in US dollars while the shares are quoted in Australian dollars. On any plausible exchange rate the implied multiple runs well into double digits, embedding expectations for label extension and pipeline delivery rather than the paediatric franchise alone. Borrowings and cash are broadly comparable, so enterprise value sits close to market capitalisation. There is no dividend and no group free cash flow, and multiples move constantly.

Founder and chief executive Silviu Itescu exercised 1,885,334 options at AUD 1.45 on 21 July and kept the shares, though an exercise is not a market purchase.

Outlook

Management has guided qualitatively to further revenue growth this financial year. The audited FY2026 accounts, due in coming weeks, will confirm or revise the preliminary USD 115 million.

The markers are concrete: activation of the remaining centres, the start of the adult graft-versus-host disease study, progress on the modular LVAD submission, and MSB-DR004 data in mid-2027. Mesoblast has first-in-class product revenue for the first time alongside a long record of slipped timelines. Both are true at once.